Compare TRVG & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRVG | SWKH |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | Germany | United States |
| Employees | N/A | 9 |
| Industry | EDP Services | Diversified Financial Services |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 198.4M |
| IPO Year | 2015 | N/A |
| Metric | TRVG | SWKH |
|---|---|---|
| Price | $2.82 | $16.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $3.95 | ★ $18.00 |
| AVG Volume (30 Days) | 23.4K | ★ 104.8K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $16.98 | ★ $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $13.32 |
| 52 Week High | $5.27 | $17.90 |
| Indicator | TRVG | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 32.19 |
| Support Level | $2.77 | $14.69 |
| Resistance Level | $2.92 | $17.08 |
| Average True Range (ATR) | 0.06 | 0.37 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 54.05 | 12.06 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.